U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C22H27N5O4
Molecular Weight 425.4809
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-04691502

SMILES

COC1=CC=C(C=N1)C2=CC3=C(C)N=C(N)N=C3N([C@H]4CC[C@@H](CC4)OCCO)C2=O

InChI

InChIKey=XDLYKKIQACFMJG-WKILWMFISA-N
InChI=1S/C22H27N5O4/c1-13-17-11-18(14-3-8-19(30-2)24-12-14)21(29)27(20(17)26-22(23)25-13)15-4-6-16(7-5-15)31-10-9-28/h3,8,11-12,15-16,28H,4-7,9-10H2,1-2H3,(H2,23,25,26)/t15-,16-

HIDE SMILES / InChI

Molecular Formula C22H27N5O4
Molecular Weight 425.4809
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27103175 | https://clinicaltrials.gov/ct2/show/NCT01420081

PF-04691502 is a PI3K/mTOR dual inhibitor. It was tested in phase 2 clinical trials against endometrial cancer and breast cancer, but its development was discontinued due to unacceptable toxicity.

Originator

Curator's Comment: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.8 nM [Ki]
16.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
102.3 ng/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-04691502 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
66.4 ng/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04691502 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1287 ng × h/mL
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-04691502 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
809.3 ng × h/mL
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04691502 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9 h
8 mg 1 times / day multiple, oral
dose: 8 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-04691502 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
13.8 h
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04691502 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
unlikely
weak
PubMed

PubMed

TitleDatePubMed
PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells.
2013 Jul 4
Patents

Sample Use Guides

In clinical trials against endometrium cancer PF-04691502 was administred orally once daily (QD) at doses 6-8 mg
Route of Administration: Oral
BT20, U87MG, and SKOV3 cells were plated at 3,000 cell/well in 96-well culture plates in growth medium with 10% FBS. Cells were incubated overnight and treated with DMSO (0.1% final) or serial diluted compound for 3 days. Resazurin (Sigma-Aldrich) was added to 0.1 mg/mL. Plates were incubated at 37°C in 5% CO2 for 3 hours. Fluorescence signals were read as emission at 590 nm after excitation at 530 nm. IC50 values were calculated by plotting fluorescence intensity to drug concentration in nonlinear curves. PF-04691502 inhibited cell proliferation of BT20, SKOV3, and U87MG with IC50 values of 313, 188, and 179 nmol/L
Substance Class Chemical
Created
by admin
on Mon Mar 31 20:54:15 GMT 2025
Edited
by admin
on Mon Mar 31 20:54:15 GMT 2025
Record UNII
4W39NS61KI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-4691502
Preferred Name English
PF-04691502
Common Name English
PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE, 2-AMINO-8-(TRANS-4-(2-HYDROXYETHOXY)CYCLOHEXYL)-6-(6-METHOXY-3-PYRIDINYL)-4-METHYL-
Systematic Name English
Code System Code Type Description
PUBCHEM
25033539
Created by admin on Mon Mar 31 20:54:15 GMT 2025 , Edited by admin on Mon Mar 31 20:54:15 GMT 2025
PRIMARY
EPA CompTox
DTXSID901026004
Created by admin on Mon Mar 31 20:54:15 GMT 2025 , Edited by admin on Mon Mar 31 20:54:15 GMT 2025
PRIMARY
DRUG BANK
DB11974
Created by admin on Mon Mar 31 20:54:15 GMT 2025 , Edited by admin on Mon Mar 31 20:54:15 GMT 2025
PRIMARY
NCI_THESAURUS
C84837
Created by admin on Mon Mar 31 20:54:15 GMT 2025 , Edited by admin on Mon Mar 31 20:54:15 GMT 2025
PRIMARY
SMS_ID
300000041340
Created by admin on Mon Mar 31 20:54:15 GMT 2025 , Edited by admin on Mon Mar 31 20:54:15 GMT 2025
PRIMARY
ChEMBL
CHEMBL1234354
Created by admin on Mon Mar 31 20:54:15 GMT 2025 , Edited by admin on Mon Mar 31 20:54:15 GMT 2025
PRIMARY
CAS
1013101-36-4
Created by admin on Mon Mar 31 20:54:15 GMT 2025 , Edited by admin on Mon Mar 31 20:54:15 GMT 2025
PRIMARY
FDA UNII
4W39NS61KI
Created by admin on Mon Mar 31 20:54:15 GMT 2025 , Edited by admin on Mon Mar 31 20:54:15 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY